Skip to main content
. 2023 Jan 30;14:1055671. doi: 10.3389/fimmu.2023.1055671

Figure 3.

Figure 3

T cell-dependent anti-tumor effects were critical for in vivo efficacy of DSP-0509 (A) LM8 cells were inoculated in C3H mice. 1 mg/kg of DSP-0509 was administered i.v. once a week from day 8. The tumor volume is the mean ± S.E.M. of each group (n=12/group), and differences were evaluated by the Dunnett test (**P<0.01). The number of metastasized nodes in the lung was evaluated 28 days after inoculation. The values are mean ± S.E.M of each group and differences were determined by the t-test (***P<0.001). (B) CT26 cells were inoculated in the subcutaneous both right and left dorsal flanks of Balb/c mice. 5 mg/kg of DSP-0509 was administered i.v. once a week from Day 7. 5% imiquimod cream was applied to primary tumor 4 times a week. The values are the mean ± S.E.M. of each group (n=6/group), and differences were determined by the Dunnett test (*P<0.05) (**P<0.01). (C) CT26 cells were inoculated in the subcutaneous dorsal flanks of Balb/c mice and Balb/c nude mice. 5 mg/kg of DSP-0509 was administered i.v. once a week from Day 5. The values are the mean ± S.E.M. of each group (n=6/group), and differences were determined by the Dunnett test (*P<0.01). (D) Each cell line was inoculated in the subcutaneous dorsal flanks of the respective host mouse. 5 mg/kg of DSP-0509 was administered i.v. once a week. The tumor volume is the mean ± S.E.M. of each group, and differences were evaluated by the Dunnett test (**P<0.01) (E) The frequency of CD8+ T cell at the tumor site in each model was analyzed by flow cytometry. Tumors were collected on days 5-10 after inoculation. Efficient in the graph means DSP-0509 reduced tumor growth statistically significant in Figure 3D . ns, not significant.